Learning Objectives Contrast the current strengths and limitations of the three main slide-
based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer …

Fehrenbacher L CR, Geyer CE, Rastogi P, et al: NSABP B-47 (NRG oncology): Phase III
randomized trial comparing adjuvant chemotherapy with adriamycin (A) and …

Amplification of the HER2 gene and/or overexpression of its protein product have been
found in up to 25% to 30% of human breast cancers and have been shown to be associated …

BACKGROUND: Molecular techniques play an increasingly important role in breast cancer
detection and help in the prediction of prognosis and treatment response. HER-2/neu …

The NCCN HER2 Testing in Breast Cancer Task Force was convened to critically evaluate
the ability of the level of HER2 expression or gene amplification in breast cancer tumors to …

Importance of the field: Differential levels of HER2 expression in normal versus HER2-
overexpressing breast carcinomas, together with the demonstration of a key role for HER2 in …

Abstract HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated
with an aggressive tumor phenotype and reduced survival rates. The HER-2 status of a …

Background Identification of HER2-positive breast cancers with high anti-HER2 sensitivity
could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based …

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial
with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …

There is strong clinical evidence that trastuzumab, a monoclonal antibody targeting the
human epidermal growth factor receptor (HER) two tyrosine kinase receptor, is an important …